vs
Orthofix Medical Inc.（OFIX）与Turning Point Brands, Inc.（TPB）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Turning Point Brands, Inc.的1.8倍（$219.9M vs $121.0M），Turning Point Brands, Inc.净利率更高（6.8% vs -1.0%，领先7.8%），Turning Point Brands, Inc.同比增速更快（29.2% vs 2.0%），Turning Point Brands, Inc.自由现金流更多（$21.5M vs $16.8M），过去两年Turning Point Brands, Inc.的营收复合增速更高（20.7% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Turning Point Australia（TPAUS）是一家位于澳大利亚的保守派游说团体，隶属于美国转折点组织但保持独立运营，由乔尔·贾马尔创立并于2023年完成注册。该团体目前正积极行动，试图影响2026年3月举行的南澳大利亚州选举结果。
OFIX vs TPB — 直观对比
营收规模更大
OFIX
是对方的1.8倍
$121.0M
营收增速更快
TPB
高出27.2%
2.0%
净利率更高
TPB
高出7.8%
-1.0%
自由现金流更多
TPB
多$4.7M
$16.8M
两年增速更快
TPB
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $121.0M |
| 净利润 | $-2.2M | $8.2M |
| 毛利率 | 71.1% | 55.9% |
| 营业利润率 | 0.2% | 16.5% |
| 净利率 | -1.0% | 6.8% |
| 营收同比 | 2.0% | 29.2% |
| 净利润同比 | 92.4% | 239.8% |
| 每股收益（稀释后） | $-0.05 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXTPB
| Q4 25 | $219.9M | $121.0M | ||
| Q3 25 | $205.6M | $119.0M | ||
| Q2 25 | $203.1M | $116.6M | ||
| Q1 25 | $193.6M | $106.4M | ||
| Q4 24 | $215.7M | $93.7M | ||
| Q3 24 | $196.6M | $90.7M | ||
| Q2 24 | $198.6M | $93.2M | ||
| Q1 24 | $188.6M | $83.1M |
净利润OFIXTPB
| Q4 25 | $-2.2M | $8.2M | ||
| Q3 25 | $-22.8M | $21.1M | ||
| Q2 25 | $-14.1M | $14.5M | ||
| Q1 25 | $-53.1M | $14.4M | ||
| Q4 24 | $-29.1M | $2.4M | ||
| Q3 24 | $-27.4M | $12.4M | ||
| Q2 24 | $-33.4M | $13.0M | ||
| Q1 24 | $-36.0M | $12.0M |
毛利率OFIXTPB
| Q4 25 | 71.1% | 55.9% | ||
| Q3 25 | 72.2% | 59.2% | ||
| Q2 25 | 68.7% | 57.1% | ||
| Q1 25 | 62.8% | 56.0% | ||
| Q4 24 | 69.0% | 56.0% | ||
| Q3 24 | 68.7% | 55.6% | ||
| Q2 24 | 67.8% | 54.1% | ||
| Q1 24 | 67.5% | 58.2% |
营业利润率OFIXTPB
| Q4 25 | 0.2% | 16.5% | ||
| Q3 25 | -8.3% | 21.8% | ||
| Q2 25 | -7.9% | 22.6% | ||
| Q1 25 | -25.2% | 21.8% | ||
| Q4 24 | -5.3% | 19.1% | ||
| Q3 24 | -9.6% | 22.9% | ||
| Q2 24 | -12.5% | 24.5% | ||
| Q1 24 | -15.6% | 23.2% |
净利率OFIXTPB
| Q4 25 | -1.0% | 6.8% | ||
| Q3 25 | -11.1% | 17.7% | ||
| Q2 25 | -6.9% | 12.4% | ||
| Q1 25 | -27.4% | 13.5% | ||
| Q4 24 | -13.5% | 2.6% | ||
| Q3 24 | -13.9% | 13.6% | ||
| Q2 24 | -16.8% | 14.0% | ||
| Q1 24 | -19.1% | 14.5% |
每股收益（稀释后）OFIXTPB
| Q4 25 | $-0.05 | $0.40 | ||
| Q3 25 | $-0.57 | $1.13 | ||
| Q2 25 | $-0.36 | $0.79 | ||
| Q1 25 | $-1.35 | $0.79 | ||
| Q4 24 | $-0.76 | $0.15 | ||
| Q3 24 | $-0.71 | $0.68 | ||
| Q2 24 | $-0.88 | $0.68 | ||
| Q1 24 | $-0.95 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $222.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $372.0M |
| 总资产 | $850.6M | $763.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXTPB
| Q4 25 | $82.0M | $222.8M | ||
| Q3 25 | $62.9M | $201.2M | ||
| Q2 25 | $65.6M | $109.9M | ||
| Q1 25 | $58.0M | $99.6M | ||
| Q4 24 | $83.2M | $48.9M | ||
| Q3 24 | $30.1M | $33.6M | ||
| Q2 24 | $26.4M | $142.2M | ||
| Q1 24 | $27.0M | $130.9M |
总债务OFIXTPB
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXTPB
| Q4 25 | $450.0M | $372.0M | ||
| Q3 25 | $442.5M | $358.2M | ||
| Q2 25 | $458.3M | $224.8M | ||
| Q1 25 | $458.3M | $203.4M | ||
| Q4 24 | $503.1M | $190.4M | ||
| Q3 24 | $525.9M | $185.7M | ||
| Q2 24 | $546.0M | $172.8M | ||
| Q1 24 | $570.3M | $160.0M |
总资产OFIXTPB
| Q4 25 | $850.6M | $763.8M | ||
| Q3 25 | $832.6M | $742.8M | ||
| Q2 25 | $837.2M | $595.8M | ||
| Q1 25 | $823.1M | $564.6M | ||
| Q4 24 | $893.3M | $493.4M | ||
| Q3 24 | $867.9M | $488.0M | ||
| Q2 24 | $882.0M | $591.6M | ||
| Q1 24 | $906.0M | $586.3M |
负债/权益比OFIXTPB
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $24.9M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $21.5M |
| 自由现金流率自由现金流/营收 | 7.6% | 17.8% |
| 资本支出强度资本支出/营收 | 4.9% | 2.8% |
| 现金转化率经营现金流/净利润 | — | 3.03× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $43.8M |
8季度趋势，按日历期对齐
经营现金流OFIXTPB
| Q4 25 | $27.7M | $24.9M | ||
| Q3 25 | $12.4M | $3.3M | ||
| Q2 25 | $11.6M | $11.8M | ||
| Q1 25 | $-18.4M | $17.4M | ||
| Q4 24 | $23.7M | $17.7M | ||
| Q3 24 | $11.7M | $13.2M | ||
| Q2 24 | $9.0M | $13.4M | ||
| Q1 24 | $-18.6M | $22.6M |
自由现金流OFIXTPB
| Q4 25 | $16.8M | $21.5M | ||
| Q3 25 | $2.5M | $-721.0K | ||
| Q2 25 | $4.5M | $7.8M | ||
| Q1 25 | $-25.1M | $15.2M | ||
| Q4 24 | $15.2M | $16.6M | ||
| Q3 24 | $6.3M | $12.6M | ||
| Q2 24 | $-360.0K | $10.9M | ||
| Q1 24 | $-29.1M | $22.3M |
自由现金流率OFIXTPB
| Q4 25 | 7.6% | 17.8% | ||
| Q3 25 | 1.2% | -0.6% | ||
| Q2 25 | 2.2% | 6.7% | ||
| Q1 25 | -13.0% | 14.3% | ||
| Q4 24 | 7.0% | 17.8% | ||
| Q3 24 | 3.2% | 13.9% | ||
| Q2 24 | -0.2% | 11.7% | ||
| Q1 24 | -15.4% | 26.8% |
资本支出强度OFIXTPB
| Q4 25 | 4.9% | 2.8% | ||
| Q3 25 | 4.8% | 3.4% | ||
| Q2 25 | 3.5% | 3.4% | ||
| Q1 25 | 3.5% | 2.1% | ||
| Q4 24 | 4.0% | 1.2% | ||
| Q3 24 | 2.7% | 0.7% | ||
| Q2 24 | 4.7% | 2.7% | ||
| Q1 24 | 5.6% | 0.4% |
现金转化率OFIXTPB
| Q4 25 | — | 3.03× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.82× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 7.34× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 1.03× | ||
| Q1 24 | — | 1.89× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
TPB
| US | $111.5M | 92% |
| Non Us | $9.6M | 8% |
